Activation of human inflammatory cells by secreted phospholipases A2

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1761, Issue 11, 2006, Pages 1289-1300

  Triggiani, Massimo ^a   Granata, Francescopaolo ^a   Frattini, Annunziata ^a   Marone, Gianni ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Chemokine; Cytokine; Inflammation; Secreted PLA2; Signal transduction

Indexed keywords

4 BROMOPHENACYL BROMIDE; ARACHIDONIC ACID; CHEMOKINE; CYTOKINE; INDOLE DERIVATIVE; ISOENZYME; LY 311727; LY 315920NA; LY 333013; LYSOPHOSPHOLIPID; MANNOSE RECEPTOR; MJ 33; OXAMETACIN; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; PHOSPHONIC ACID DERIVATIVE; PROTEOHEPARAN SULFATE; S 3013; SB 203347; UNCLASSIFIED DRUG; VARESPLADIB;

ACUTE LUNG INJURY; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ASTHMA; BACTERICIDAL ACTIVITY; CELL ACTIVATION; CELL INTERACTION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DEGRANULATION; DRUG EFFECT; EFFECTOR CELL; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME MECHANISM; ENZYME RELEASE; EOSINOPHIL; EXOCYTOSIS; HUMAN; INFLAMMATION; INFLAMMATORY CELL; INFLAMMATORY DISEASE; MACROPHAGE; MAST CELL; MAST CELL DEGRANULATION; MEDIATOR; MEDIATOR RELEASE; MEMBRANE BINDING; MONOCYTE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

AUTOIMMUNE DISEASES; CELL DEGRANULATION; EXOCYTOSIS; HEPARITIN SULFATE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LECTINS, C-TYPE; LEUKOCYTES; MACROPHAGE ACTIVATION; MANNOSE-BINDING LECTINS; PHOSPHOLIPASES A; PROTEIN BINDING; PROTEOGLYCANS; RECEPTORS, CELL SURFACE;

EID: 33750952878     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2006.07.003     Document Type: Review

References (132)

1. 2 enzymes. Prostaglandins Other Lipid Mediat. 68-69 (2002) 3-58
2. 2 enzymes: classification and characterization. Biochim. Biophys. Acta 1488 (2000) 1-19
3. 2 from snake venom to human secreted forms. J. Mol. Evol. 31 (1990) 228-238
4. 2. Toxicon 27 (1989) 613-635
5. 2. Rev. Physiol. Biochem. Pharmacol. 91 (1981) 91-203
6. 2 in inflammatory and allergic diseases: not just enzymes. J. Allergy Clin. Immunol. 116 (2005) 1000-1006
7. 2 from human synovial fluid in rheumatoid arthritis. J. Biochem. (Tokyo) 105 (1989) 395-399
8. 2 present in rheumatoid arthritic synovial fluid. J. Biol. Chem. 264 (1989) 5335-5338
9. 2 in human acute pancreatitis. Scand. J. Gastroenterol. 15 (1980) 633-636
10. 2 levels: correlation with the hemodynamic and pulmonary changes in gram-negative septic shock. J. Lab. Clin. Med. 104 (1984) 873-881
11. 2 as an index of disease activity in rheumatoid arthritis. Prospective double blind study of 212 patients. J. Rheumatol. 23 (1996) 1162-1166
12. 2 in serum and colonic mucosa in ulcerative colitis. Scand. J. Clin. Lab. Invest. 59 (1999) 279-287
13. 2 mass concentration in serum and colonic mucosa in Crohn's disease. Clin. Chem. Lab. Med. 36 (1998) 751-755
14. 2 activities are increased in human adult respiratory distress syndrome. Am. J. Physiol. 269 (1995) L109-L118
15. 2 and arachidonate increase in bronchoalveolar lavage fluid after inhaled antigen challenge in asthmatics. Am. J. Respir. Crit. Care Med. 155 (1997) 421-425
16. Chilton F.H., Averill F.J., Hubbard W.C., Fonteh A.N., Triggiani M., and Liu M.C. Antigen-induced generation of lyso-phospholipids in human airways. J. Exp. Med. 183 (1996) 2235-2245
17. 2 from human nasal lavage. Am. J. Respir. Cell Mol. Biol. 11 (1994) 108-113
18. 2 induces an inflammatory response in rabbit joints. J. Immunol. 146 (1991) 3904-3910
19. 2 in rabbits. J. Invest. Dermatol. 86 (1986) 380-383
20. 2-induced pathophysiologic changes in the guinea pig lung. Am. J. Pathol. 136 (1990) 1283-1291
21. 2-induced pulmonary and hemodynamic responses in the guinea pig. Effects of enzyme inhibitors and mediators antagonists. Am. Rev. Respir. Dis. 142 (1990) 1193-1199
22. 2 in the pathobiology of disease. Lab. Invest. 55 (1986) 391-404
23. 2 and their receptors and binding proteins. Biochim. Biophys. Acta 1488 (2000) 59-70
24. 2 in human serum. Biochim. Biophys. Acta 1733 (2005) 210-223
25. 2. J. Biol. Chem. 264 (1989) 5768-5775
26. 2 in granules and secrete active enzyme in response to soluble stimuli. Biochem. Biophys. Res. Commun. 208 (1995) 650-656
27. 2. Blood 91 (1998) 3037-3043
28. 4 release. J. Pharmacol. Exp. Ther. 284 (1998) 847-857
29. 2 induced by interactions of human platelets with monocytes. Ann. Hematol. 69 (1994) 307-310
30. 2 preferentially expressed in type 2 helper T cells. J. Biol. Chem. 276 (2001) 18321-18326
31. 2 plays a role in arachidonic acid release and eicosanoid biosynthesis by mast cells. J. Immunol. 152 (1994) 5438-5446
32. 2 by guinea pig alveolar macrophages. Dissociation from arachidonic acid liberation and modulation by dexamethasone. J. Immunol. 151 (1993) 5613-5623
33. 2 up-regulates cyclooxygenase-2 and amplifies cytokine-mediated prostaglandin production in human rheumatoid synoviocytes. J. Immunol. 165 (2000) 2790-2797
34. 2 in malignant and non-malignant human gastric mucosa. Br. J. Cancer 68 (1993) 103-111
35. 2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 300-309
36. 2 antigen in arthritic synovium. Ann. Rheum. Dis. 57 (1998) 550-558
37. 2 in mast cells and macrophages in normal human ileal submucosa and in Crohn's disease. Clin. Chem. Lab. Med. 38 (2000) 1231-1236
38. 2 enzymes are expressed in rheumatoid arthritis and augment prostaglandin production in cultured synovial cells. FEBS J. 272 (2005) 655-672
39. 2 enzymes in several human tissues. Biochim. Biophys. Acta 1736 (2005) 200-210
40. 2 in human digestive organs. J. Histochem. Cytochem. 40 (1992) 1659-1664
41. 2 induced prominent release of arachidonic acid from human myeloid leukemia cells. J. Biol. Chem. 274 (1999) 34203-34211
42. 2 in human lung airway epithelial cells. Am. J. Respir. Cell. Mol. Biol. 23 (2000) 37-44
43. 2 enzymes in lungs of humans with pneumonia and their potential prostaglandin-synthetic function in human lung-derived cells. Biochem. J. 387 (2005) 27-38
44. 2 in rodents during inflammation. Biochim. Biophys. Acta 1635 (2003) 37-47
45. 2s in human neutrophils: role in eicosanoid production and gram-negative bacterial phospholipid hydrolysis. J. Biol. Chem. 277 (2002) 5061-5073
46. 2 protein interaction. J. Clin. Invest. 102 (1998) 1152-1160
47. 2 in human lung macrophages expressing the M-type receptor. J. Immunol. 174 (2005) 464-474
48. 2. J. Biol. Chem. 277 (2002) 48535-48549
49. 2 induce cytokine release from blood and synovial fluid monocytes. Eur. J. Immunol. 32 (2002) 67-76
50. 2. Annu. Rev. Biochem. 64 (1995) 653-688
51. 2 with the glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan in the cyclooxygenase-2-mediated delayed prostanoid-biosynthetic pathway. J. Biol. Chem. 274 (1999) 29927-29936
52. 2 and decorin in human atherosclerotic lesions. Circ. Res. 86 (2000) 707-714
53. 2 type II binds to extracellular matrix biglycan: modulation of its activity on LDL by colocalization in glycosaminoglycan matrixes. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1934-1941
54. 2 with apoptotic human T cells: role of heparan sulfate proteoglycans. FASEB J. 17 (2003) 1068-1080
55. 2. Blood 102 (2003) 2901-2909
56. 2s in human embryonic kidney 293 and rat mastocytoma RBL-2H3 cells through heparan sulfate shuttling and external plasma membrane mechanisms. J. Biol. Chem. 276 (2001) 10083-10096
57. 2 contribute to arachidonic acid release and prostaglandin production in rat gastric mucosal cells and transfected human embryonic kidney cells. J. Biol. Chem. 281 (2006) 16245-16255
58. 2 translocates to the phagosome after zymosan stimulation of mouse peritoneal macrophages and regulates phagocytosis. J. Biol. Chem. 281 (2006) 6691-6698
59. 2. Trends Pharmacol. Sci. 20 (1999) 162-170
60. Lambeau G., Barhanin J., Schweitz H., Qar J., and Lazdunski M. Identification and properties of very high affinity brain membrane-binding sites for a neurotoxic phospholipase from the taipan venom. J. Biol. Chem. 264 (1989) 11503-11510
61. 2 in skeletal muscle. J. Biol. Chem. 265 (1990) 9526-9532
62. 2: the N-terminal region is more important than enzymatic activity. Biochemistry 45 (2006) 5800-5816
63. 2 involved in N-type receptor binding and neurotoxicity. J. Biol. Chem. 272 (1997) 7173-7181
64. 2. Molecular cloning, identification of a secreted soluble form, expression, and chromosomal localization. J. Biol. Chem. 270 (1995) 8963-8970
65. 2 and TNF-receptor superfamily signaling: implications for the inflammatory response in atherogenesis. Circ. Res. 91 (2002) 681-688
66. 2 receptor on neutrophils and its role in elastase release and adhesion. Am. J. Physiol.: Cell Physiol. 283 (2002) C1102-C1113
67. 2 are natural ligands of the mouse 180-kDa M-type receptor. J. Biol. Chem. 274 (1999) 7043-7051
68. 2 receptor. FEBS Lett. 478 (2000) 187-191
69. 2 on their M-type 180-kDa membrane receptor. J. Biol. Chem. 270 (1995) 28869-28873
70. 2 involved in the binding to M-type receptors. J. Biol. Chem. 270 (1995) 5534-5540
71. 2. Biochemistry 34 (1995) 13146-13151
72. 2. J. Biol. Chem. 271 (1996) 250-257
73. East L., and Isacke C.M. The mannose receptor family. Biochim. Biophys. Acta 1572 (2002) 364-386
74. 2 is recognized by the macrophage mannose receptor. Arch. Biochem. Biophys. 324 (1995) 78-84
75. 2 induce β-glucuronidase release and IL-6 production from human lung macrophages. J. Immunol. 164 (2000) 4908-4915
76. 2. J. Immunol. 151 (1993) 5675-5684
77. 2-induced Mac-1 expression on human neutrophils. J. Leukocyte Biol. 60 (1996) 174-180
78. 2 activate selective functions in human eosinophils. J. Immunol. 170 (2003) 3279-3288
79. 2 in human lung macrophages. Eur. J. Immunol. 36 (2006) 1938-1950
80. 2 isotypes. J. Immunol. 167 (2001) 4161-4171
81. 2 stimulates CXC chemokine ligand 8 production via ERK and NF-kappaB in human neutrophils. J. Immunol. 173 (2004) 6433-6439
82. 2 induce the expression of chemokines in microvascular endothelium. Biochem. Biophys. Res. Commun. 300 (2003) 731-737
83. Rizzo M.T., Nguyen E., Aldo-Benson M., and Lambeau G. Secreted phospholipase A(2) induces vascular endothelial cell migration. Blood 96 (2000) 3809-3815
84. 2: a role for cell surface glycosaminoglycans. Biochem. Pharmacol. 63 (2002) 65-72
85. 2 in the stimulation of neutrophil motility by cobra venoms. Toxicon 41 (2003) 459-468
86. 2 induces dendritic cell maturation. Eur. J. Immunol. 34 (2004) 2293-2302
87. 2. Blood 105 (2005) 3583-3587
88. 2 neurotoxins and lysophospholipid-fatty acid mixtures. Science 310 (2005) 1678-1680
89. 2 and beta-neurotoxicity. Biochimie 82 (2000) 807-814
90. 2-potentiated inducible nitric oxide synthase expression by macrophages requires NF-kappa B activation. J. Immunol. 164 (2000) 6359-6365
91. 2 receptor-involved inducible nitric oxide synthase expression. J. Immunol. 170 (2003) 2093-2099
92. 2 promotes matrix metalloproteinase-2-mediated cell migration via the phosphatidylinositol-3 kinase and Akt pathway. J. Biol. Chem. 279 (2004) 36579-36585
93. 2-induced matrix metalloproteinase-2 activation. Biochem. Biophys. Res. Commun. 340 (2006) 1278-1283
94. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J. Pathol. 200 (2003) 448-464
95. 2 in Swiss 3T3 cells via specific binding site. J. Biol. Chem. 266 (1991) 19139-19141
96. 2 stimulates the growth of human pancreatic cancer cell line. FEBS Lett. 373 (1995) 85-87
97. 2 generates anti-apoptotic survival signals in kidney fibroblasts. J. Biol. Chem. 274 (1999) 27726-27733
98. Tessier C., Hichami A., and Khan N.A. Implication of three isoforms of PLA(2) in human T-cell proliferation. FEBS Lett. 520 (2002) 111-116
99. 2 in a human pancreatic cancer cell line. FEBS Lett. 407 (1997) 343-346
100. 2 stimulates inducible nitric oxide synthase expression via ERK and NF-kB in macrophages. Eur. J. Immunol. 31 (2001) 2709-2717
101. 2 in murine bone marrow-derived mast cells. J. Immunol. 165 (2000) 2773-2782
102. 2 induces phospholipase Cgamma-1 activation and Ca2+ mobilization in the human astrocytoma cell line 1321N1 by a mechanism independent of its catalytic activity. Biochem. Biophys. Res. Commun. 260 (1999) 99-104
103. 2 in the human astrocytoma cell line 1321N1. J. Biol. Chem. 273 (1998) 606-612
104. 2 elicits proinflammatory changes and upregulates the surface expression of fas ligand in monocytic cells: potential relevance for atherogenesis. Circ. Res. 90 (2002) 38-45
105. 2. J. Biol. Chem. 277 (2002) 36479-36488
106. Dong C., Davis R.J., and Flavell R.A. MAP kinases in the immune response. Annu. Rev. Immunol. 20 (2002) 55-72
107. Grinstein S., Furuya W., Butler J.R., and Tseng J. Receptor-mediated activation of multiple serine/threonine kinases in human leukocytes. J. Biol. Chem. 268 (1993) 20223-20231
108. Valledor A.F., Comalada M., Xaus J., and Celada A. The differential time-course of extracellular-regulated kinase activity correlates with the macrophage response toward proliferation or activation. J. Biol. Chem. 275 (2000) 7403-7409
109. Boulay F., Naik N., Giannini E., Tardif M., and Brouchon L. Phagocyte chemoattractant receptors. Ann. N. Y. Acad. Sci. 832 (1997) 69-84
110. Lu Y., and Wahl L.M. Production of matrix metalloproteinase-9 by activated human monocytes involves a phosphatidylinositol-3 kinase/Akt/IKK{alpha}/NF-{kappa}B pathway. J. Leukocyte Biol. 78 (2005) 259-265
111. Park S.J., Lee S.C., Hong S.H., and Kim H.M. Degradation of IkappaBalpha in activated RAW264.7 cells is blocked by the phosphatidylinositol 3-kinase inhibitor LY294002. Cell Biol. Toxicol. 18 (2002) 121-130
112. Edmunds J.W., and Mahadevan L.C. MAP kinases as structural adaptors and enzymatic activators in transcription complexes. J. Cell Sci. 117 (2004) 3715-3723
113. 2 group IIA. Curr. Med. Chem. 12 (2005) 3011-3026
114. 2 inhibitor: a new class of anti-inflammatory drugs, SPI. J. Pharmacol. Exp. Ther. 288 (1999) 1117-1124
115. 2 in animal models of acute lung injury. Eur. Respir. J. 21 (2003) 1040-1045
116. 2 inhibitor in rabbit acute lung injury: correlation with lung surfactant protection. Crit. Care Med. 29 (2001) 719-727
117. 2 in rat colitis induced by dextran sulfate sodium. Eur. J. Pharmacol. 472 (2003) 147-158
118. 2, S-5920/LY315920Na, on experimental acute pancreatitis in rats. J. Pharmacol. Sci. 96 (2004) 144-154
119. 2, in patients with suspected sepsis and organ failure. Crit. Care Med. 31 (2003) 718-728
120. 2 inhibitor on inhaled allergen challenge in subjects with asthma. J. Asthma 42 (2005) 65-71
121. 2, in the treatment of rheumatoid arthritis. J. Rheumatol. 32 (2005) 417-423
122. 2, fails to improve clinical outcome for patients with severe sepsis. Crit. Care Med. 33 (2005) 1741-1748
123. 2-independent mechanisms. Biochim. Biophys. Acta 1438 (1999) 213-222
124. 2 by indole analogues: a structure-guided study. Bioorg. Med. Chem. 12 (2004) 1737-1749
125. 2 against Pseudomonas aeruginosa clinical isolates. J. Med. Microbiol. 52 (2003) 1039-1045
126. 2. J. Biol. Chem. 277 (2002) 5849-5857
127. 2. J. Clin. Invest. 102 (1998) 633-638
128. 2 inhibits replication of T-cell tropic HIV-1 strains via interaction with the CXCR4 chemokine receptor. Mol. Pharmacol. 60 (2001) 341-347
129. 2, a new class of HIV inhibitors that block virus entry into host cells. J. Clin. Invest. 104 (1999) 611-618
130. 2. J. Biol. Chem. 280 (2005) 29989-29992
131. 2 inhibitor. Am. J. Physiol.: Gastrointest. Liver Physiol. 285 (2003) G586-G592
132. 2. Chin. Med. Sci. J. 19 (2004) 6-12